Lung Cancer Social Media #LCSM Chat,
JTO Research Watch: "Nivolumab or Nivolumab Plus Ipilimumab in Patients with Relapsed Malignant Pleural Mesothelioma (IFCT-1501…
JTO Research Watch: "Nivolumab or Nivolumab Plus Ipilimumab in Patients with Relapsed Malignant Pleural Mesothelioma (IFCT-1501…
Anti-PD-1 nivolumab monotherapy or nivolumab plus anti-CTLA-4 ipilimumab combination therapy both showed promising activity in…
JTO Research Watch: "Nivolumab or Nivolumab Plus Ipilimumab in Patients with Relapsed Malignant Pleural Mesothelioma (IFCT-1501…
Pubblicati su Lancet Oncology interessanti dati sulla immunoterapia come trattamento del mesotelioma recidivante. I risultati…